NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.
Read more at globenewswire.comFavorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
Barchart·07/16/2026 14:22:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.